BCAA and L-Alanine Composition for Muscle Wasting Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments and supplements fail to effectively prevent or treat muscle wasting associated with pathological and age-related conditions, such as muscular dystrophy, cancer-associated cachexia, and sarcopenia, by not adequately maintaining muscle mass and function.
Innovation Solution
A composition comprising branched-chain amino acids (BCAAs) and L-Alanine, in specific weight ratios, is administered to enhance plasma and muscle absorption, thereby improving muscle function and maintaining muscle mass.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCAAs are administered alone, then protein synthesis is stimulated and proteolysis is inhibited, but plasma and muscle absorption is insufficient to effectively prevent or treat muscle wasting
Solution Approach 1:
L-Alanine acts as an intermediary substance that facilitates the absorption and transport of BCAAs into muscle tissue. The patent demonstrates that L-Alanine enhances BCAA uptake by providing a carrier mechanism that overcomes the limited direct absorption capacity of BCAAs alone, thereby resolving the contradiction between BCAA's protein synthesis stimulation and insufficient absorption.
Solution Approach 2:
The invention combines BCAAs and L-Alanine into a composite amino acid formulation where the two substances work synergistically. This composite approach allows L-Alanine to enhance BCAA absorption while BCAAs provide the primary substrate for protein synthesis, achieving both improved absorption and therapeutic effectiveness simultaneously.
2Strength
If standard amino acid supplements are used, then some protein synthesis support is provided, but they fail to adequately maintain muscle mass and function in pathological conditions
Solution Approach 1:
The invention changes the compositional parameters of amino acid supplements by specifically formulating a combination of BCAAs (Leucine, Isoleucine, Valine) with L-Alanine in optimized ratios. This parameter change transforms standard supplements into a targeted formulation that addresses the specific metabolic needs of muscle wasting conditions, thereby simultaneously improving muscle strength maintenance and reliability in pathological states.
Data Source
AI summary
The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the amino acid L-Alanine and their use in the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions.